Plasma Amino Acids Up in Non-Alcoholic Fatty Liver Disease

This article originally appeared here.
Share this content:
Plasma Amino Acids Up in Non-Alcoholic Fatty Liver Disease
Plasma Amino Acids Up in Non-Alcoholic Fatty Liver Disease

WEDNESDAY, Aug. 16, 2017 (HealthDay News) -- In non-alcoholic fatty liver disease (NAFLD), increased plasma amino acid (AA) concentrations are observed, according to a study published online Aug. 12 in Hepatology.

Melania Gaggini, from the Institute of Clinical Physiology in Pisa, Italy, and colleagues examined whether individuals with NAFLD non-obese (NAFLD-NO) versus obese (NAFLD-Ob) had altered plasma AAs compared with controls, and whether concentrations correlated with insulin resistance (IR) and liver histology. The authors measured AA profile in NAFLD subjects with liver biopsy, without diabetes (29 NAFLD-NO and 15 NAFLD-Ob), and 20 non-obese controls.

The researchers found that most AAs were increased only in NAFLD-Ob. Compared with controls, only alanine, glutamine, isoleucine, and valine, but not leucine, were increased in NAFLD-NO. There were correlations for glutamate, tyrosine, and glutamate/(serine+glycine) (GSG-index) with hepatic-IR. Independently of body mass index (BMI), GSG-index correlated with liver enzymes, in particular gamma glutamyl transferase. There were associations for ballooning and/or inflammation at liver biopsy with increased plasma branched chain AAs and aromatic AAs, and mild associations with GSG-index; in this cohort, only the new GSG-index was able to discriminate fibrosis F3 to 4 versus F0 to 2.

"Increased plasma AA concentrations were observed mainly in obese NAFLD, likely as a consequence of increased IR and protein catabolism," the authors write. "The GSG-index is a possible new marker of severity of liver disease independently of BMI."

Abstract
Full Text (subscription or payment may be required)

Share this content:

is free, fast, and customized just for you!

Already a member?

Sign In Now »

Drug Lookup

Browse drugs by: BrandGenericDisease

Trending Activities

All Professions


Sign up for myCME e-newsletters


More in Home

FDA OKs Nucala for Eosinophilic Granulomatosis With Polyangiitis

FDA OKs Nucala for Eosinophilic Granulomatosis With Polyangiitis

First drug to be approved for rare autoimmune disease that leads to vasculitis

Findings Support Individualized Glycemic Control in T2DM

Findings Support Individualized Glycemic Control in T2DM

Approach saved $13,547/patient vs uniform intensive control, with lower medication costs

Atherosclerosis ID'd in Many Without CV Risk Factors

Atherosclerosis ID'd in Many Without CV Risk Factors

LDL-C independently associated with the presence and extent of atherosclerosis

is free, fast, and customized just for you!

Already a member?

Sign In Now »